The BM microenvironment has a critical role in regulating the proliferation and differentiation of hematopoietic stem cells (HSCs) . Recent research has demonstrated that such a microenvironment, the so-called stem cell niche, exists in the osteoblast neighborhood and the blood vessel endothelial cell neighborhood. 1 Osteoblasts have been shown to take part in the maintenance and proliferation of HSCs. Further, osteoclasts have a critical role in the mobilization of peripheral HSCs. 2 Although the mechanism by which G-CSF mobilizes PBSCs has been extensively studied, it is still not fully understood. Wnt signaling has been shown to have a central role in the development and homeostasis of bone and also has been implicated in the regulation of hematopoiesis. 3 To evaluate the biological role of Wnt signaling and osteoclastogenesis in G-CSF-induced PBSC mobilization, we examined serum and plasma levels of Dickkopf-1 (Dkk1), soluble receptor activator of nuclear factor-kB ligand (sRANKL), and osteoprotegerin (OPG) in normal healthy donors for allogeneic PBSC transplantation.
The protocol described was approved by our Institutional Review Board. The study participants were 21 healthy donors with a median age of 36 years (range, 14--55 years). After obtaining written informed consent, G-CSF (lenograstim, 10 mg/kg per day or filgrastim, 400 mg/m 2 per day) was s.c. administered for 5 days, and apheresis was performed on days 4 and 5. Blood samples from the donors were collected on days 0 and 4, that is, before and during G-CSF-induced PBSC mobilization. On day 4, blood was collected before apheresis to avoid any effects of apheresis on marker levels. After blood collection, serum and plasma from each sample were immediately separated by centrifugation, transferred into cryotubes and stored at À80 1C until further processing. The number of CD34 þ cells collected was determined by flow cytometric analysis. Marker levels were measured using ELISAs, according to the manufacturer's protocol. The ELISA kits for Dkk1, sRANKL and OPG were purchased from Biomedica Gruppe (Wien, Austria). Data are presented as mean±s.e.. Differences in marker levels before and during G-CSF treatment were analyzed using the Wilcoxon signed-rank test. P-values of o0.05 were considered significant.
We found that serum levels of Dkk1 were significantly decreased and that plasma levels of sRANKL were significantly elevated after G-CSF administration (49.28 ± 9.71 ng/mL --38.10 ± 15.92 ng/mL and 0.24 ± 0.26 ng/mL --2.68 ± 0.51 ng/mL, respectively). In contrast, there was no significant change in plasma levels of OPG after the administration of G-CSF (1.66 ± 1.17 mg/ mL --1.37 ± 0.62 mg/mL) ( Figure 1 ). We also examined the relationship between marker levels and various factors related to PBSC collection, including the number of CD34 þ cells, neutrophils and monocytes. We did not find any correlation between marker levels and any of these cell counts (data not shown).
Here, we have shown for the first time that serum levels of the Wnt antagonist Dkk1 are suppressed after G-CSF treatment in healthy PBSC donors. By binding to the Wnt coreceptor lipoprotein-related protein-5, Dkk1 regulates Wnt signalingmediated effects on bone differentiation, adipogenesis and hematopoiesis. 4 Recently, Fleming et al. 5 showed that a reduction in HSC Wnt signaling resulted in reduced p21Cip1 expression, increased cell cycling and a progressive decline in regenerative function after transplantation using osteoblast-specific Dkk1 transgenic mice. Moreover, Aicher et al. 6 reported that recombinant Dkk1 regulated canonical Wnt signaling in endosteal cells such as osteoblasts and osteoclasts in the BM and mobilized vasculogenic progenitor cells in mice. Both reports indicate that Dkk1 has a role in regulating the fate of HSCs by Wnt signaling. The impact of the Wnt family on the expansion and regulation of HSCs has been examined in numerous studies. However, the physiological effects of this pathway remain somewhat ill-defined, with often contradictory results. 7 Our finding that G-CSF decreased serum Dkk1 levels suggests that Wnt signaling in HSCs and/or stem cell niches is involved in G-CSF-induced PBSC mobilization in humans as well as in mice. Further investigation is needed to elucidate the mechanism underlying the decreased serum Dkk1 levels associated with G-CSF. Recombinant RANKL has been shown to mobilize HSCs in a mouse model. 2 In the present study, we showed that G-CSF induced the expression of plasma sRANKL in healthy donors. This result suggests that G-CSF-induced osteoclastogenesis is involved in the mobilization of PBSCs. In contrast, our data show that plasma levels of OPG, a soluble decoy receptor of RANKL, had no consistent tendency after G-CSF administration. OPG is secreted by many cell types in addition to osteoblasts, including those in the heart, kidney, liver and spleen. A previous study reported that B cells may be responsible for 64% of the total BM OPG production. 8 Various mechanisms other than alterations in sRANKL may determine plasma OPG levels. We found no correlation between various surrogate markers related to PBSC collection, including CD34 þ cell, neutrophil and monocyte counts, and the measured levels of Dkk1 and sRANKL. This result likely reflects the small size of our sample. A larger-scale study is required to further evaluate this relationship. However, because a significant change in Dkk1 and sRANKL levels was observed after 4 days of G-CSF administration, it is possible that a dynamic change in HSCs and the stem cell niche indeed occurred during G-CSF administration. Further studies are necessary to determine the exact role of Dkk1 and sRANKL in PBSC mobilization. Our findings may encourage future exploitation of the modulator of Wnt signaling and bone remodeling for therapeutic HSC mobilization and engraftment.
